Oligomerization mannuronic acid and application of medicinal salts of oligomerization mannuronic acid in leucopenia prevention medicines

A technology for polymannuronic acid and leukopenia, which is applied to the application field of oligomannuronic acid or its medicinal salt in the preparation of medicines for preventing and treating leukopenia, can solve the problems of inaccurate curative effect and high price, and achieves the Increase the number, promote proliferation, improve the effect of forming

Active Publication Date: 2013-02-13
MARINE BIOMEDICAL RES INST OF QINGDAO CO LTD
View PDF0 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] Aiming at the shortcomings of inaccurate curative effect and high price of drugs for treating leukopenia in the prior art, the present invention pr

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Oligomerization mannuronic acid and application of medicinal salts of oligomerization mannuronic acid in leucopenia prevention medicines
  • Oligomerization mannuronic acid and application of medicinal salts of oligomerization mannuronic acid in leucopenia prevention medicines
  • Oligomerization mannuronic acid and application of medicinal salts of oligomerization mannuronic acid in leucopenia prevention medicines

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0035] Embodiment 1, the preparation of oligomeric mannuronic acid

[0036] The invention adopts an acid degradation method to prepare and separate high-molecular-weight polymannuronic acid from alginate alginate, and then further undergoes acid degradation or enzymatic degradation to obtain the oligomannuronic acid of the invention.

[0037] Prepare alginate with water to make a glue solution with a concentration of 2%, hydrolyze it in 0.5mol / L hydrochloric acid solution at 100°C for 10 hours, and discard the supernatant after static cooling. Dissolve the precipitate in 2% Na 2 CO 3 In the aqueous solution, the pH value was adjusted to 2.85 with dilute hydrochloric acid, and the precipitate was removed by centrifugation. Then add hydrochloric acid to the supernatant until the acid concentration in the system reaches 0.3 mol / L, and stir and degrade at 100° C. for 5 hours. The precipitate was then separated and dissolved in 2% Na 2 CO 3 In the aqueous solution, adjust the ...

Embodiment 2

[0044] Embodiment 2, the effect of oligomannuronic acid on mouse leukopenia caused by cyclophosphamide

[0045] According to the internationally recognized method, its effect on leukopenia induced by cyclophosphamide in mice was evaluated, and its mechanism of action was preliminarily studied at the cellular level.

[0046] Mouse intraperitoneal injection of cyclophosphamide caused leukopenia model, observed the effect of oligomannuronic acid on the number of white blood cells in the peripheral blood of mice, and determined the number of nucleated cells in the bone marrow of mice, and studied the effect of drug administration on mice in vivo. Effects on the colonization of hematopoietic progenitor cells of the granulo-macrophage lineage.

[0047] The specific experimental method is as follows: 60 Kunming mice were randomly divided into 6 groups according to body weight, normal control group, model control group, lithium carbonate positive control group, and three dose groups o...

Embodiment 3

[0054] Embodiment 3, the impact of in vitro administration of oligomannuronic acid on CFU-GM

[0055] In vitro agar culture method was used to study the effect of in vitro administration of oligomannuronic acid on normal mouse bone marrow cells and the effect of cyclophosphamide inhibiting mouse bone marrow cells on CFU-GM.

[0056] 1) The effect on the formation of CFU-GM in bone marrow cells of normal mice: take normal mice, routinely separate bone marrow cells, take RPMI-1640 culture medium and adjust the bone marrow cells to a concentration of 1×10 6 ·ml -1 Perform colony culture. Different concentrations of drugs were added to the experimental group, so that the final concentrations were 3.125ug / ml, 6.25ug / ml, 12.5ug / ml, 25ug / ml and 50ug / ml, and the same volume of RPMI-1640 culture solution was added to the control group. Add the above culture system into a 24-well plate, 0.5ml per well, set 3 duplicate wells for each concentration, and place at 37°C, 5% CO 2 cultured ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Weight average molecular weightaaaaaaaaaa
Login to view more

Abstract

The invention provides oligomerization mannuronic acid and application of medicinal salts of oligomerization mannuronic acid in leucopenia prevention medicine. In in-vitro cell experiments, oligomerization mannuronic acid can obviously promote forming of colony-forming unit-granulocyte macrophage (CFU-GM), simultaneously can promote marrow stroma cells to breed and secrete CFU-GM and promote splenic lymphocytes to secrete interleukin-3. In vivo experiments further indicates that oligomerization mannuronic acid can obviously restrain reduction of white blood cells in mice caused by cyclophosphamide, increase the number marrow nucleated cell of the mice and promote forming of CFU-GM. Experiment results indicate that oligomerization mannuronic acid can be developed to be a clinical medicine capable of effectively preventing leucopenia.

Description

technical field [0001] The invention belongs to the field of marine medicines, and in particular relates to the application of oligomannuronic acid or a medicinal salt thereof in the preparation of medicines for preventing and treating leukopenia. Background technique [0002] The total number of white blood cells in normal blood is 4~10×10 9 / L, when the body is affected by drugs or other external factors, the number of white blood cells in the blood is continuously lower than 4×10 9 / L, that is called leukopenia (Leukopenia). Since granulocytes are the main component of white blood cells, leukopenia is most commonly caused by neutropenia, with an absolute value of neutrophils below 1.8 to 2.0×10 9 / L, called neutropenia (Neutropenia). [0003] Leukopenia is a common serious side effect in tumor radiotherapy and chemotherapy. It can cause the body's immunity to decline, and patients are prone to colds, and even easily induce repeated infections. The drugs used clinicall...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/715A61P7/00
Inventor 管华诗李春霞李海花胡婷李全才于广利
Owner MARINE BIOMEDICAL RES INST OF QINGDAO CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap